Syngene International (SYNGENE) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue from operations reached Rs 8,745 million, up 11% year-over-year, with net profit at Rs 867 million, a 59% increase year-over-year.

• Research services drove growth, accounting for 67% of sales, with strong pilot-to-contract conversions.

• Operational milestones included commissioning Unit 3 biologics facility, inaugurating a peptide lab, and acquiring a US biologics site, increasing bioreactor capacity to 50,000L.

• Leadership team strengthened with key hires in biology, technology, and strategy.

• Recognized as the most sustainable pharma/biotech company in India and among the World's Most Sustainable Companies in 2025.

Financial highlights

• Revenue from operations for Q1 FY26: Rs 8,745 million (11% YoY growth); total consolidated income: Rs 8,922 million.

• EBITDA for Q1 FY26: Rs 2,241 million (19% YoY growth); EBITDA margin at 25%.

• PAT before exceptional items: Rs 867 million (59% YoY growth); PAT margin at 10%.

• Net cash position as of June 30, 2025: Rs 10,528 million after CapEx spending.

• Basic EPS for Q1 FY26 was Rs 2.16, up from Rs 1.89 in Q1 FY25.

Outlook and guidance

• Full-year guidance maintained: underlying revenue growth in early teens, reported growth in mid-single digits.

• EBITDA margins expected in the mid-20s for FY26; depreciation to rise as new facilities come online.

• Inventory adjustments in biologics expected to impact growth trajectory in coming quarters.

• Focus on expanding integrated drug discovery, development, and manufacturing services across small and large molecules.

• Continued investments in operational excellence, digital transformation, and ESG initiatives to drive long-term value.